Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1989 Aug;28(2):188–192. doi: 10.1111/j.1365-2125.1989.tb05415.x

Investigations on plasma activity of low molecular weight heparin after intravenous and oral administrations.

M Dryjski 1, D E Schneider 1, P Mojaverian 1, B S Kuo 1, T D Bjornsson 1
PMCID: PMC1379904  PMID: 2550047

Abstract

This study investigated the absorption of low molecular weight heparin (LMWH) after oral administration in man. Six healthy subjects received 5,000 anti-Xa units of LMWH (Kabi 2165) by both i.v. and oral administration. The oral formulations were prepared in pH 4.0 and pH 7.0 buffered solutions. Multiple blood samples were collected after each dose for measurements of anti-Xa, anti-IIa and APTT plasma heparin activities. Pharmacokinetic parameters based on the anti-Xa activity measurements after the i.v. dose were as follows (mean +/- s.d.): t1/2, 1.82 +/- 0.23 h; V, 4.34 +/- 0.651; and CL, 28.0 +/- 6.2 ml min-1. Half-life values based on the anti-IIa and APTT activities were 1.63 +/- 0.43 and 1.09 +/- 0.51 h, respectively. Considerable prolongations in APTT were observed, with APTT at 30 min averaging 55.7 +/- 4.1 s (1.84 +/- 0.27 times baseline values). After oral administration, no measurable plasma heparin activities were observed with either LMWH preparation. The results of this investigation indicate that LMWH does not have detectable plasma activity after oral administration, and that after i.v. administration it has significant anti-IIa and APTT activities in addition to its anti-Xa activity.

Full text

PDF
188

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Andersson L. O., Barrowcliffe T. W., Holmer E., Johnson E. A., Sims G. E. Anticoagulant properties of heparin fractionated by affinity chromatography on matrix-bound antithrombin iii and by gel filtration. Thromb Res. 1976 Dec;9(6):575–583. doi: 10.1016/0049-3848(76)90105-5. [DOI] [PubMed] [Google Scholar]
  2. Bjornsson T. D., Wolfram K. M. Intersubject variability in the anticoagulant response to heparin in vitro. Eur J Clin Pharmacol. 1982;21(6):491–497. doi: 10.1007/BF00542044. [DOI] [PubMed] [Google Scholar]
  3. Bjornsson T. D., Wolfram K. M., Kitchell B. B. Heparin kinetics determined by three assay methods. Clin Pharmacol Ther. 1982 Jan;31(1):104–113. doi: 10.1038/clpt.1982.16. [DOI] [PubMed] [Google Scholar]
  4. Bratt G., Törnebohm E., Lockner D., Bergström K. A human pharmacological study comparing conventional heparin and a low molecular weight heparin fragment. Thromb Haemost. 1985 Apr 22;53(2):208–211. [PubMed] [Google Scholar]
  5. Bratt G., Törnebohm E., Widlund L., Lockner D. Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers. Thromb Res. 1986 Jun 1;42(5):613–620. doi: 10.1016/0049-3848(86)90340-3. [DOI] [PubMed] [Google Scholar]
  6. Bârzu T., Molho P., Tobelem G., Petitou M., Caen J. P. Binding of heparin and low molecular weight heparin fragments to human vascular endothelial cells in culture. Nouv Rev Fr Hematol. 1984;26(4):243–247. [PubMed] [Google Scholar]
  7. Doutremépuich C., Masse A., Oca C., Maury M. O., Gestreau J. L., Toulemonde F., Lormeau J. C. Absorption duodénale d'une héparine de bas poids moléculaire chez le lapin. Pathol Biol (Paris) 1984 Jan;32(1):45–48. [PubMed] [Google Scholar]
  8. Engel R. H., Riggi S. J. Intestinal absorption of heparin facilitated by sulfated or sulfonated surfactants. J Pharm Sci. 1969 Jun;58(6):706–709. doi: 10.1002/jps.2600580612. [DOI] [PubMed] [Google Scholar]
  9. Holmer E., Kurachi K., Söderström G. The molecular-weight dependence of the rate-enhancing effect of heparin on the inhibition of thrombin, factor Xa, factor IXa, factor XIa, factor XIIa and kallikrein by antithrombin. Biochem J. 1981 Feb 1;193(2):395–400. doi: 10.1042/bj1930395. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Koh T. Y., Bharucha K. R. Intestinal absorption of stable heparinic acid complexes. J Lab Clin Med. 1972 Jul;80(1):47–55. [PubMed] [Google Scholar]
  11. LOOMIS T. A. Absorption of heparin from the intestine. Proc Soc Exp Biol Med. 1959 Jul;101(3):447–449. doi: 10.3181/00379727-101-24974. [DOI] [PubMed] [Google Scholar]
  12. Larsen A. K., Lund D. P., Langer R., Folkman J. Oral heparin results in the appearance of heparin fragments in the plasma of rats. Proc Natl Acad Sci U S A. 1986 May;83(9):2964–2968. doi: 10.1073/pnas.83.9.2964. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Larsen M. L., Abildgaard U., Teien A. N., Gjesdal K. Assay of plasma heparin using thrombin and the chromogenic substrate H-D-Phe-Pip-Arg-pNA (S-2238). Thromb Res. 1978 Aug;13(2):285–288. doi: 10.1016/0049-3848(78)90016-6. [DOI] [PubMed] [Google Scholar]
  14. Murray G. D., Best C. H. THE USE OF HEPARIN IN THROMBOSIS. Ann Surg. 1938 Aug;108(2):163–177. doi: 10.1097/00000658-193808000-00002. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Sue T. K., Jaques L. B., Yuen E. Effects of acidity, cations and alcoholic fractionation on absorption of heparin from gastrointestinal tract. Can J Physiol Pharmacol. 1976 Aug;54(4):613–617. doi: 10.1139/y76-084. [DOI] [PubMed] [Google Scholar]
  16. Teien A. N., Lie M., Abildgaard U. Assay of heparin in plasma using a chromogenic substrate for activated factor X. Thromb Res. 1976 Mar;8(3):413–416. doi: 10.1016/0049-3848(76)90034-7. [DOI] [PubMed] [Google Scholar]
  17. WINDSOR E., CRONHEIM G. E. Gastro-intestinal absorption of heparin and synthetic heparinoids. Nature. 1961 Apr 15;190:263–264. doi: 10.1038/190263a0. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES